Tüdőrák: vizsgálatok itt: Egyesült Királyság
153 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Where
- Canterbury, Central Middlesbrough, London, Portsmouth
- Életkor
- 18 év and over
- People
- 614 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00 - 1/2. fázisFut, nem toborozFiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Where
- London
- Életkor
- 18 év and over
- People
- 334 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06303505 · EU 2024-511074-80-01 - 2. fázisTaking peopleA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Where
- Greater London, Liverpool, London, Manchester, Sutton, Torquay
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06667076 · EU 2025-520730-28-00 - 2. fázisTaking peopleA Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Where
- London
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT06667908 · EU 2024-518276-32-00 - No phaseTaking peopleA Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
- Where
- Bath, Cardiff, Eastbourne, Guildford, Heath Town, London, Manchester, Sutton
- Életkor
- 18 év and over
- People
- 380 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07230691 - 2/3. fázisTaking peopleSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Where
- Basildon, Bath, Brighton, Cardiff, Chelsea, Cottingham, Glasgow, Liverpool, London, Manchester, Norwich, Oxford, Preston, Sheffield, Southampton, Taunton, Wolverhampton, York
- Életkor
- 18 év and over
- People
- 1580 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00 - 3. fázisTaking peopleClinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Where
- Belfast, Birmingham, Bodelwyddan, Cardiff, Edinburgh, Guildford, London, Southampton, Truro, Wrexham
- Életkor
- 18 év to 90 év
- People
- 507 worldwide
- Run by
- ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00 - 3. fázisTaking peopleStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Where
- London, Manchester
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- ArriVent BioPharma, Inc.
See details and how to joinNCT07185997 - 3. fázisTaking peopleBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Cardiff, Edinburgh, London, Manchester, Sutton
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00 - 2/3. fázisTaking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Birmingham, Edinburgh, Kent, Leicester, London, Manchester, Surrey
- Életkor
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - 1. fázisTaking peopleStudy of XB010 in Subjects With Solid Tumors
- Where
- Leicester, London, Manchester
- Életkor
- 18 év and over
- People
- 396 worldwide
- Run by
- Exelixis
See details and how to joinNCT06545331 - No phaseTaking peopleUnderstanding the Feasibility of a Co-designed Pre-radiotherapy Exercise Programme - A Single-arm Study
- Where
- Belfast
- Életkor
- 18 év and over
- People
- 30
- Run by
- Queen's University, Belfast
See details and how to joinNCT07554677 - 3. fázisTaking peopleA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Birmingham, London, Manchester, Nottingham
- Életkor
- 18 év and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne, Preston
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00 - 1. fázisTaking peopleA Study of MGC026 in Participants With Advanced Solid Tumors
- Where
- Oxford, Sutton
- Életkor
- 18 év and over
- People
- 394 worldwide
- Run by
- MacroGenics
See details and how to joinNCT06242470 - 3. fázisTaking peoplePhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Where
- Cheltenham, Inverness, London, Norwich, Preston, Truro
- Életkor
- 18 év and over
- People
- 675 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Where
- Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne, Torquay
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00 - 1/2. fázisTaking peopleStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Where
- Cardiff, Leicester
- Életkor
- 18 év and over
- People
- 252 worldwide
- Run by
- AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00 - 3. fázisTaking peopleStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Where
- Eastbourne, London, Londonderry, Nottingham
- Életkor
- 18 év and over
- People
- 686 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Aberdeen, Cambridge, Cardiff, Guildford, London, Middlesbrough, Norwich, Sutton, Wolverhampton
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00 - 2. fázisTaking peopleA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Where
- Birmingham, Guildford, London
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07680764 · EU 2026-525170-19-00 - 3. fázisTaking peopleStudy of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
- Where
- Manchester
- Életkor
- 18 év and over
- People
- 695 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06801834 - No phaseTaking peopleOptimizing Patient Treatment With EPA-enriched Nutrition, a Randomised Control Trial
- Where
- Edinburgh, Gateshead, Liverpool
- Életkor
- 18 év and over
- People
- 118 worldwide
- Run by
- University of Edinburgh
See details and how to joinNCT07255066 - No phaseTaking peoplePRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
- Where
- Bristol, Edinburgh, Maidstone, Manchester, Nottingham, Sheffield, Sutton
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04790253 - 3. fázisTaking peopleA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Where
- Cambridge, Chelsea, London, Nottingham, Stoke-on-Trent, Sutton, Wolverhampton
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146